Concepedia

Waldo Feliu Ortuzar

WF

Statistics

Publications

3

Citations

43

H-Index

3

Active since

2013

Affiliations

Mayo Clinic in Arizona(Current)

Eli Lilly (United States)

Boston Biomedical (United States)

Texas Oncology

The University of Texas MD Anderson Cancer Center

Waldo Feliu Ortuzar is an author at Mayo Clinic in Arizona specializing in medicine, pharmacology, and oncology.

Publications per year

2013–2017

3

Publications

3

Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

Ralph Zinner, Helen J. Ross, Robert Weaver et al. · Journal of Clinical Oncology · 2013 · 22 citations

, , +17

BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).

Bassel F. El‐Rayes, Donald Richards, Allen Lee Cohn et al. · Journal of Clinical Oncology · 2017 · 11 citations

, , +14

BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer.

Tim Larson, Waldo Feliu Ortuzar, Tanios Bekaii‐Saab et al. · Journal of Clinical Oncology · 2017 · 10 citations

, , +17

1–3 of 3